We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$380M
AUM Growth
-$34.7M
Cap. Flow
-$16.7M
Cap. Flow %
-4.4%
Top 10 Hldgs %
55.07%
Holding
91
New
23
Increased
22
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
OFIX icon
Orthofix Medical
OFIX
+$13.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.1M
3
CNC icon
Centene
CNC
+$12.1M
4
MCK icon
McKesson
MCK
+$7.93M
5
AVTR icon
Avantor
AVTR
+$6.38M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$21.3M
2
COR icon
Cencora
COR
+$15.3M
3
XRAY icon
Dentsply Sirona
XRAY
+$9.62M
4
BDX icon
Becton Dickinson
BDX
+$8.66M
5
SIBN icon
SI-BONE Inc
SIBN
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 70.45%
2 Miscellaneous 29.55%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$46M 12.12%
101,900
+41,000
+67% +$18.3M
CNC icon
2
Centene
CNC
$32.6B
$18.4M 4.84%
218,235
+147,426
+208% +$12.1M
LH icon
3
Labcorp
LH
$26.3B
$16.2M 4.26%
71,329
-4,764
-6% -$1.12M
AZN icon
4
AstraZeneca
AZN
$253B
$15.9M 4.2%
120,136
-42,228
-26% -$5.06M
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$14.2M 3.75%
+194,684
New +$13.1M
OFIX icon
6
Orthofix Medical
OFIX
$363M
$14.2M 3.75%
434,803
+415,986
+2,211% +$13.4M
HUM icon
7
Humana
HUM
$46.2B
$12.7M 3.34%
29,120
-4,861
-14% -$2.03M
THC icon
8
Tenet Healthcare
THC
$21.4B
$11.3M 2.97%
131,376
-15,553
-11% -$1.28M
SYNH
9
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$9.98M 2.63%
123,232
+47,957
+64% +$4.06M
AVTR icon
10
Avantor
AVTR
$10.6B
$9.67M 2.55%
285,901
+178,905
+167% +$6.38M
BIO icon
11
Bio-Rad Laboratories Class A
BIO
$10.1B
$9.66M 2.54%
17,151
+2,612
+18% +$1.57M
HOLX
12
DELISTED
Hologic
HOLX
$9.5M 2.5%
123,624
-57,444
-32% -$4.13M
SIBN icon
13
SI-BONE Inc
SIBN
$831M
$9.34M 2.46%
413,370
-353,756
-46% -$7.34M
MCK icon
14
McKesson
MCK
$103B
$8.93M 2.35%
+29,168
New +$7.93M
CI icon
15
Cigna
CI
$74.1B
$6.88M 1.81%
28,717
-7,929
-22% -$1.86M
ELUT icon
16
Elutia
ELUT
$35.9M
$6.6M 1.74%
1,109,479
+33,839
+3% +$200K
EW icon
17
Edwards Lifesciences
EW
$51.5B
$5.25M 1.38%
+44,561
New +$5M
ISRG icon
18
Intuitive Surgical
ISRG
$135B
$5.2M 1.37%
+17,232
New +$5.03M
EHC icon
19
Encompass Health
EHC
$12.2B
$4.67M 1.23%
+82,526
New +$4.31M
OCUL icon
20
Ocular Therapeutix
OCUL
$2.17B
$4.57M 1.2%
923,963
+206,820
+29% +$1.15M
ADAP
21
DELISTED
Adaptimmune Therapeutics
ADAP
$4.45M 1.17%
2,160,890
+1,263,311
+141% +$3.41M
RNAC icon
22
Cartesian Therapeutics
RNAC
$239M
$4.25M 1.12%
115,065
+44,281
+63% +$2.77M
XBI icon
23
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$4.17M 1.1%
46,440
-2,466
-5% -$228K
AXSM icon
24
Axsome Therapeutics
AXSM
$11.1B
$4.15M 1.09%
100,299
+44,670
+80% +$1.38M
AHCO icon
25
AdaptHealth
AHCO
$788M
$3.98M 1.05%
248,314
+150,388
+154% +$2.7M
1
2 3 4

Similar funds

UVM
Upfront Ventures Management Santa Monica, California $12.3M AUM
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Endurant Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Endurant Capital Management held 91 positions worth $380M, down 8.4% from $414M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Endurant Capital Management withdrew a net $16.7M in Q1 2022, closing 28 positions and reducing 16 holdings. Its most notable exit was Sanofi, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 72% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Endurant Capital Management opened a new position in Bristol-Myers Squibb worth $14.2M.

  • Endurant Capital Management's largest Q1 2022 buy was Bristol-Myers Squibb: 194,684 shares worth $14.2M.
  • Endurant Capital Management added most to Orthofix Medical in Q1 2022, an estimated $13.4M increase.
  • Endurant Capital Management's biggest Q1 2022 reduction was SI-BONE Inc, cutting an estimated $7.34M.
  • Endurant Capital Management fully exited Sanofi in Q1 2022, selling an estimated $21.3M.
  • Endurant Capital Management's ten largest holdings make up 55% of its $380M portfolio in Q1 2022.
  • Endurant Capital Management opened 23 new positions and closed 28 in Q1 2022.
  • Endurant Capital Management's portfolio value fell 8.4% quarter-over-quarter to $380M.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.